STN SEARCH 9/19/03 R. Ihan

Welcome to STN International! Enter x:x

LOGINID:ssspta1200rxh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International

Web Page URLs for STN Seminar Schedule - N. America NEWS "Ask CAS" for self-help around the clock NEWS CA/CAplus records now contain indexing from 1907 to the NEWS SEP 09 NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE Identification of STN records implemented NEWS Jul 21 Polymer class term count added to REGISTRY NEWS Jul 21 6 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and NEWS 7 Jul 22 Right Truncation available New pricing for EUROPATFULL and PCTFULL effective AUG 05 NEWS 8 August 1, 2003 Field Availability (/FA) field enhanced in BEILSTEIN 9 AUG 13 NEWS PATDPAFULL: one FREE connect hour, per account, in NEWS 10 AUG 15 September 2003 NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in September 2003 RDISCLOSURE: one FREE connect hour, per account, in NEWS 12 AUG 15 September 2003 TEMA: one FREE connect hour, per account, in NEWS 13 AUG 15 September 2003 Data available for download as a PDF in RDISCLOSURE AUG 18 NEWS 14 Simultaneous left and right truncation added to PASCAL NEWS 15 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Righ NEWS 16 AUG 18 Truncation Simultaneous left and right truncation added to ANABSTR NEWS 17 AUG 18

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:33:56 ON 19 SEP 2003

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

## FULL ESTIMATED COST

SESSION ENTRY 0.63 0.63

FILE 'USPATFULL' ENTERED AT 13:35:33 ON 19 SEP 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Sep 2003 (20030918/PD) FILE LAST UPDATED: 18 Sep 2003 (20030918/ED) HIGHEST GRANTED PATENT NUMBER: US6622308 HIGHEST APPLICATION PUBLICATION NUMBER: US2003177560 CA INDEXING IS CURRENT THROUGH 18 Sep 2003 (20030918/UPCA) ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Sep 2003 (20030918/PD) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<< >>> original, i.e., the earliest published granted patents or <<< >>> applications. USPAT2 contains full text of the latest US <<< publications, starting in 2001, for the inventions covered in <<< USPATFULL. A USPATFULL record contains not only the original <<< >>> published document but also a list of any subsequent <<< publications. The publication number, patent kind code, and <<< publication date for all the US publications for an invention <<< are displayed in the PI (Patent Information) field of USPATFULL <<< >>> records and may be searched in standard search fields, e.g., /PN, <<< <<< /PK, etc. >>> USPATFULL and USPAT2 can be accessed and searched together <<< through the new cluster USPATALL. Type FILE USPATALL to <<< enter this cluster. <<< >>> <<< >>> >>> Use USPATALL when searching terms such as patent assignees, <<< classifications, or claims, that may potentially change from <<< <<< >>> the earliest to the latest publication.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s cortisol/ti,ab

13 CORTISOL/TI 57 CORTISOL/AB

57 CORTISOL/TI, AB L1

=> s (antagonist or antagonists)/ti,ab

655 ANTAGONIST/TI

2584 ANTAGONIST/AB

2794 ANTAGONISTS/TI

5687 ANTAGONISTS/AB

8874 (ANTAGONIST OR ANTAGONISTS)/TI,AB

=> s 11 and 12

10 L1 AND L2 L3

=> d 13 1-10

ANSWER 1 OF 10 USPATFULL on STN L3

2003:246905 USPATFULL AN

Methods of treating mild cognitive impairment using a TΤ

glucocorticoid-specific receptor antagonist Schatzberg, Alan F., Los Altos, CA, United States IN

Belanoff, Joseph K., Woodside, CA, United States

Corcept Therapeutics, Inc., Menlo Park, CA, United States (U.S. PA corporation)

```
20030916
PT
       US 6620802
                          В1
       US 2000-717703
                                20001120 (9)
AΙ
PRAI
       US 1999-167432P
                            19991123 (60)
DT
       Utility
       GRANTED
FS
LN.CNT 1210
INCL
       INCLM: 514/178.000
NCL .
       NCLM: 514/178.000
       [7]
IC
       ICM: A61K031-56
EXF
       514/178
     ANSWER 2 OF 10 USPATFULL on STN
L3
       2003:93613 USPATFULL
AN
       Methods for inhibiting cognitive deterioration in adults with down's
TI
       syndrome
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Corcept Therapeutics, Inc. (U.S. corporation)
PΑ
       US 2003064974
                                20030403
                          A1
PΙ
       US 2002-230575
                          Α1
                                20020828 (10)
ΑI
                            20010831 (60)
PRAI
       US 2001-316653P
DT ·
       Utility
       APPLICATION
FS
LN.CNT 1295
       INCLM: 514/179.000
INCL
       NCLM: 514/179.000
NCL
       [7]
IC
       ICM: A61K031-573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 3 OF 10 USPATFULL on STN
L3
       2003:38155 USPATFULL
AN
       Methods for preventing antipsychotic-induced weight gain
ΤI
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Schatzberg, Alan F., Los Altos, CA, UNITED STATES
       Corcept Therapeutics, Inc. (U.S. corporation)
PA
                                20030206
                          Α1
PΙ
       US 2003027802
                                20020722 (10)
       US 2002-201356
                          Α1
ΑI
                           20010723 (60)
       US 2001-307693P
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 1123
       INCLM: 514/171.000
INCL
       INCLS: 514/220.000; 514/259.410; 514/419.000
NCL
              514/171.000
       NCLM:
       NCLS: 514/220.000; 514/259.410; 514/419.000
IC
       [7]
       ICM: A61K031-56
       ICS: A61K031-551; A61K031-405; A61K031-519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 4 OF 10 USPATFULL on STN
L3
       2002:301607 USPATFULL
AN
       Methods for treating stress disorders using glucocorticoid
ΤI
       receptor-specific antagonists
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Corcept Therapeutics, Inc. (U.S. corporation)
PΑ
                                20021114
       US 2002169152
                          Α1
PΙ
       US 2002-102448
                          Α1
                                20020319 (10)
ΑI
                            20010323 (60)
PRAI
       US 2001-278523P
DT
       Utility
FS
       APPLICATION
LN.CNT 1140
       INCLM: 514/179.000
INCL
```

```
NCL
       NCLM: 514/179.000
IC
       [7]
       ICM: A61K031-57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    ANSWER 5 OF 10 USPATFULL on STN
L3
       2002:106303 USPATFULL
AN
       Compositions for delivery of a cortisol antagonist
TI
       Marin, Per, Vastra Frolunda, SWEDEN
TN
       Landh, Tomas, Lund, SWEDEN
       Ostholm, Ivan, Goteborg, SWEDEN
       CORTENDO AB. (non-U.S. corporation)
PA
                                20020509
                          A1
       US 2002055512
PΙ
                          A1
                                20010316 (9)
       US 2001-809979
ΑI
       Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,
RLI
       UNKNOWN
                           20000121
PRAI
       GB 2000-1449
DT
       Utility
       APPLICATION
FS
LN.CNT 1462
       INCLM: 514/254.070
INCL
NCL
       NCLM: 514/254.070
ΙĈ
       [7]
       ICM: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 6 OF 10 USPATFULL on STN
L3
       2002:75422 USPATFULL
ΑN
       Methods for treating dementia
TI
       Schatzberg, Alan F., Los Altos, CA, United States
IN
       Belanoff, Joseph K., Woodside, CA, United States
       The Board of Trustees of the Leland Stanford Junior University,
PA
       Stanford, CA, United States (U.S. corporation)
                                20020409
PΙ
       US 6369046
                          В1
                                19990204 (9)
       US 1999-246780
AΙ
                           19980515 (60)
PRAI
       US 1998-85703P
DТ
       Utility
       GRANTED
FS
LN.CNT 1433
       INCLM: 514/167.000
INCL
       INCLS: 514/169.000
       NCLM: 514/167.000
NCL
       NCLS:
             514/169.000
       [7]
IC
       ICM: A61K031-59
       ICS: A61K031-56
       514/167; 514/169
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 7 OF 10 USPATFULL on STN
L3
       2002:69990 USPATFULL
AN
       4-aza steroids
TΙ
       Pribish, James R., Sharonville, OH, United States
IN
       Gates, Cynthia A., Fairfield, OH, United States
       Weintraub, Philip M., Cincinnati, OH, United States
       Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S.
PΑ
       corporation)
                                20020402
       US 6365597
                           В1
ΡI
                                19970211 (8)
       US 1997-798258
ΑI
       US 1996-46877P
                           19960214 (60)
PRAI
DT
       Utility
FS
       GRANTED
LN.CNT 2915
       INCLM: 514/284.000
INCL
```

```
INCLS: 546/077.000; 546/078.000
       NCLM: 514/284.000
NCL
       NCLS: 546/077.000; 546/078.000
IC
       [7]
       ICM: A61K031-44
       ICS: C07D221-18; C07D221-22; A61P017-10
       546/77; 546/78; 514/284
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 8 OF 10 USPATFULL on STN
L3
       2002:63894 USPATFULL
AN
       Methods for treating psychosis associated with cocaine addiction with
ΤI
       glucocorticoid receptor antagonists
       Schatzberg, Alan F., Los Altos, CA, United States
IN
       Belanoff, Joseph K., Cupertino, CA, United States
       The Board of Trustees of the Leland Stanford Junior University, Palo
PA
       Alto, CA, United States (U.S. corporation)
                          В1
                               20020326
       US 6362173
PΙ
                               20000815 (9)
       US 2000-639377
AΙ
       Continuation of Ser. No. US 1999-244457, filed on 4 Feb 1999, now
RLI
       patented, Pat. No. US 6150349 Continuation of Ser. No. WO 1998-US20906,
       filed on 5 Oct 1998
                           19971006 (60)
PRAI
       US 1997-60973P
DT
       Utility
       GRANTED
FS
LN.CNT 1515
       INCLM: 514/179.000
INCL
       NCLM: 514/179.000
NCL
IC
       [7]
       ICM: A61K031-56
       514/179
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 9 OF 10 USPATFULL on STN
L3
       2002:32724 USPATFULL
AN
       20-Fluoro-17(20)-vinyl steroids
ΤI
       Peet, Norton P., North Andover, MA, UNITED STATES
IN.
       Weintraub, Philip M., Warren, NJ, UNITED STATES
       Burkhart, Joseph P., Plainfield, IN, UNITED STATES
       Gates, Cynthia A., Cambridge, MA, UNITED STATES
                                20020214
       US 2002019548
                          A1
PΙ
                          B2
                                20020702
       US 6413951
                               20010621 (9)
       US 2001-886818
                          A1
AΙ
       GB 2001-1523
                           20010119
PRAI
                           20010514 (60)
       US 2001-290881P
                           20000627 (60)
       US 2000-214561P
DT
       Utility
       APPLICATION
FS
LN.CNT 2407
       INCLM: 552/515.000
INCL
       INCLS: 552/606.000; 514/177.000; 514/182.000
              514/177.000
NCL
       NCLM:
             514/182.000; 552/515.000; 552/530.000; 552/532.000
       NCLS:
IC
       [7]
       ICM: C07J041-00
       ICS: A61K031-56; C07J007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 10 OF 10 USPATFULL on STN
L3
       2000:157400 USPATFULL
AN
       Methods for treating psychosis associated with glucocorticoid related
ΤI
       dysfunction
       Schatzberg, Alan F., Los Altos, CA, United States
TN
       Belanoff, Joseph K., Cupertino, CA, United States
```

```
The Board of Trustees of the Leland Stanford Junior University, Palo
PΑ
       Alto, CA, United States (U.S. corporation)
                                20001121
ΡI
       US 6150349
                                19990204 (9)
ΑI
       US 1999-244457
       Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998
RLI
       US 1997-60973P 19971006 (60)
PRAI
DT
       Utility
FS
       Granted
LN.CNT 1515
       INCLM: 514/179.000
       NCLM: 514/179.000
NCL
       [7]
IC
       ICM: A61K031-56
EXF
       514/179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
=> d 6 hit
     ANSWER 6 OF 10 USPATFULL on STN
L3
       This invention generally pertains to the field of psychiatry. In
AB
       particular, this invention pertains to the discovery that agents which
       inhibit the binding of cortisol to its receptors can be used
       in methods for treating dementia. Mifepristone, a potent glucocorticoid
       receptor antagonist, can be used in these methods. The
       invention also provides a kit for treating dementa in a human including
       a glucoccrticoid receptor antagonist and instructional
       material teaching the indications, dosage and schedule of administration
       of the glucocoticoid receptor antagonist.
=> s (corisol(2a) (antagonist or antagonists))
             4 CORISOL
         29439 ANTAGONIST
         34696 ANTAGONISTS
             0 (CORISOL(2A) (ANTAGONIST OR ANTAGONISTS))
L4
=> s (cortisol(2a) (antagonist or antagonists))
          2763 CORTISOL
         29439 ANTAGONIST
         34696 ANTAGONISTS
            12 (CORTISOL(2A) (ANTAGONIST OR ANTAGONISTS))
L5
=> d 15 1-12
     ANSWER 1 OF 12 USPATFULL on STN
1.5
       2003:246905 USPATFULL
AN
       Methods of treating mild cognitive impairment using a
TI
       glucocorticoid-specific receptor antagonist
       Schatzberg, Alan F., Los Altos, CA, United States
IN
       Belanoff, Joseph K., Woodside, CA, United States
       Corcept Therapeutics, Inc., Menlo Park, CA, United States (U.S.
PA
       corporation)
       US 6620802
                          B1
                               20030916
PT
       US 2000-717703
                               20001120 (9)
AΙ
       US 1999-167432P
                           19991123 (60)
PRAI
       Utility
DT
FS
       GRANTED
LN.CNT 1210
TNCL
       INCLM: 514/178.000
       NCLM: 514/178.000
NCL
IC
       [7]
       ICM: A61K031-56
EXF
       514/178
```

```
ANSWER 2 OF 12 USPATFULL on STN
L5
       2003:93613 USPATFULL
AN
       Methods for inhibiting cognitive deterioration in adults with down's
TI
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Corcept Therapeutics, Inc. (U.S. corporation)
PA
PΙ
       US 2003064974
                          A1 . 20030403
                                20020828 (10)
                          Α1
AΙ
       US 2002-230575
                           20010831 (60)
       US 2001-316653P
PRAI
DT
       Utility
FS
       APPLICATION
LN.CNT 1295
INCL
       INCLM: 514/179.000
       NCLM:
             514/179.000
NCL
IC
       [7]
       ICM: A61K031-573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 3 OF 12 USPATFULL on STN
       2003:38155 USPATFULL
AN
       Methods for preventing antipsychotic-induced weight gain
TI
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Schatzberg, Alan F., Los Altos, CA, UNITED STATES
PA
       Corcept Therapeutics, Inc. (U.S. corporation)
                                20030206
PΙ
       US 2003027802
                          Α1
                                20020722 (10)
       US 2002-201356
                          Α1
AΤ
                           20010723 (60)
       US 2001-307693P
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 1123
       INCLM: 514/171.000
INCL
       INCLS: 514/220.000; 514/259.410; 514/419.000
NCL
              514/171.000
              514/220.000; 514/259.410; 514/419.000
       NCLS:
IC
       [7]
       ICM: A61K031-56
       ICS: A61K031-551; A61K031-405; A61K031-519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 4 OF 12 USPATFULL on STN
L5
AN
       2003:17457 USPATFULL
ΤI
       Preparation for diagnostic of the metabolic syndrome and diseases
       including the syndrome
       Marin, Per, Goteborg, SWEDEN
IN
PΙ
       US 2003013209
                          A1
                                20030116
       US 2002-179904
                          A1
                                20020625 (10)
AΙ
       Division of Ser. No. US 1998-952638, filed on 26 Feb 1998, GRANTED, Pat.
RLI
       No. US 6410339
       Utility
DT
       APPLICATION
FS
LN.CNT 196
       INCLM: 436/518.000
INCL
       INCLS: 436/071.000; 436/500.000; 435/003.000; 435/004.000
NCL
       NCLM:
              436/518.000
              436/071.000; 436/500.000; 435/003.000; 435/004.000
       NCLS:
IC
       [7]
       ICM: G01N033-543
       ICS: G01N033-92; C12Q003-00; C12Q001-00; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 5 OF 12 USPATFULL on STN
L5
       2002:301607 USPATFULL
ΑN
TТ
       Methods for treating stress disorders using glucocorticoid
```

```
receptor-specific antagonists
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
IN
       Corcept Therapeutics, Inc. (U.S. corporation)
PA
       US 2002169152
                          A1
                                20021114
PΙ
                                20020319 (10)
ΑI
       US 2002-102448
                          Α1
                            20010323 (60)
PRAI
       US 2001-278523P
DT
       Utility
       APPLICATION
FS
LN.CNT 1140
       INCLM: 514/179.000
INCL
       NCLM: 514/179.000
NCL
IC
       [7]
       ICM: A61K031-57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 6 OF 12 USPATFULL on STN
L_5
       2002:106303 USPATFULL
ΑN
       Compositions for delivery of a cortisol antagonist
TI
       Marin, Per, Vastra Frolunda, SWEDEN
ΤN
       Landh, Tomas, Lund, SWEDEN
       Ostholm, Ivan, Goteborg, SWEDEN
       CORTENDO AB. (non-U.S. corporation)
PA
                                20020509
       US 2002055512
                          A1
PΙ
                          A1
                                20010316 (9)
       US 2001-809979
AΙ
       Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,
RLI
       UNKNOWN
                            20000121
       GB 2000-1449
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 1462
       INCLM: 514/254.070
INCL
       NCLM: 514/254.070
NCL
IC
       [7]
       ICM: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 7 OF 12 USPATFULL on STN
L5
       2002:75422 USPATFULL
AN
       Methods for treating dementia
ΤI
       Schatzberg, Alan F., Los Altos, CA, United States
IN
       Belanoff, Joseph K., Woodside, CA, United States
       The Board of Trustees of the Leland Stanford Junior University,
PA
       Stanford, CA, United States (U.S. corporation)
                                20020409
       US 6369046
                          В1
PΙ
                                19990204 (9)
       US 1999-246780
ΑI
                            19980515 (60)
       US 1998-85703P
PRAI
       Utility
DT
FS
       GRANTED
LN.CNT 1433
       INCLM: 514/167.000
INCL
       INCLS: 514/169.000
             514/167.000
NCL
       NCLM:
       NCLS:
              514/169.000
IC
       [7]
       ICM: A61K031-59
       ICS: A61K031-56
EXF
       514/167; 514/169
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 8 OF 12 USPATFULL on STN
L5
       2001:118224 USPATFULL
AN
       Nuclear receptor ligands and ligand binding domains
ΤI
       Scanlan, Thomas S., San Francisco, CA, United States
IN
       Baxter, John D., San Francisco, CA, United States
```

```
Fletterick, Robert J., San Francisco, CA, United States
       Wagner, Richard L., San Francisco, CA, United States
       Kushner, Peter J., San Francisco, CA, United States
       Apriletti, James J., Berkeley, CA, United States
       West, Brian L., San Francisco, CA, United States
       Shiau, Andrew K., San Francisco, CA, United States
       Regents of the University of California, Oakland, CA, United States
PA
       (U.S. corporation)
                               20010724
PΙ
       US 6266622
                          В1
                               19971126 (8)
AΙ
       US 1997-980115
       Continuation-in-part of Ser. No. US 1996-764870, filed on 13 Dec 1996
RLI
                           19951213 (60)
       US 1995-8540P
PRAI
                           19951213 (60)
       US 1995-8543P
       US 1995-8606P
                           19951214 (60)
DT
       Utility
       GRANTED
FS
LN.CNT 18910
       INCLM: 702/022.000
INCL
       INCLS: 702/019.000; 702/020.000; 530/350.000
NCL
              702/022.000
       NCLM:
              530/350.000; 702/019.000; 702/020.000
       NCLS:
       [7]
IC
       ICM: G06F019-00
       ICS: G06F017-00; C07G014-00
       702/19; 702/21; 702/22; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 9 OF 12 USPATFULL on STN
L5
       2001:76593 USPATFULL
AN
       Nuclear receptor ligands and ligand binding domains
TI
       Scanlan, Thomas S., 2525 Moraga St., San Francisco, CA, United States
IN
       94122
       Baxter, John D., 131 San Pablo Ave., San Francisco, CA, United States
       94127
       Fletterick, Robert J., 15 Christopher Ave., San Francisco, CA, United
       States 94131
       Wagner, Richard L., 1704 Waller St., San Francisco, CA, United States
       94117
       Kushner, Peter J., 1362 6th Ave., San Francisco, CA, United States
       94122
       Apriletti, James, 11 Virginia Gardens, Berkeley, CA, United States
       94702
       West, Brian, 142 Anderson St., San Francisco, CA, United States 94110
       Shiau, Andrew K., 34 Hugo St. #3, San Francisco, CA, United States
       94122
       US 6236946
                          B1
                               20010522
PΙ
                               19961213 (8)
       US 1996-764870
ΑI
       US 1995-8540P
                           19951213 (60)
PRAI
                           19951213 (60)
       US 1995-8543P
                           19951214 (60)
       US 1995-8606P
DT
       Utility
       Granted
FS
LN.CNT 3042
       INCLM: 702/022.000
INCL
       INCLS: 702/019.000; 702/020.000; 530/350.000
              702/022.000
NCL
       NCLM:
              530/350.000; 702/019.000; 702/020.000
       NCLS:
IC
       [7]
       ICM: G06F019-00
       ICS: G06F017-00; C07K014-00
       702/14; 702/21; 702/22; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 10 OF 12 USPATFULL on STN

L5

```
1999:75623 USPATFULL
AN
       Use of pyruvate and anti-cortisol compounds in a method for enhancing
ΤI
       physical endurance and athletic endurance in a mammal
       Beale, Paxton K., 1801 Bush St., Suite 300, San Francisco, CA, United
IN
       States 94109
       US 5919767
                                19990706
PΙ
       US 1998-27522
                               19980223 (9)
ΑI
       Division of Ser. No. US 1996-686820, filed on 26 Jul 1996, now patented,
RLI
       Pat. No. US 5756469
DT
       Utility
       Granted
FS
LN.CNT 484
       INCLM: 514/023.000
INCL
       INCLS: 514/053.000; 514/078.000
              514/023.000
NCL
       NCLM:
              514/053.000; 514/078.000
       NCLS:
IC
       [6]
       ICM: A61K031-70
       ICS: A61K031-715; A61K031-685
       514/23; 514/53; 514/78
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 11 OF 12 USPATFULL on STN
L5
       1999:19138 USPATFULL
AN
       Low dosage treatment for cocaine craving and withdrawal
ΤI
       Goeders, Nicholas E., Shreveport, LA, United States
IN
       Board of Supervisors of Louisiana State University and Agricultural and
PA
       Mechanical College, Baton Rouge, LA, United States (U.S. corporation)
                               19990209
PΙ
       US 5869474
                               19970516 (8)
       US 1997-857376
ΑI
       Utility
DT
       Granted
FS
LN.CNT 732
       INCLM: 514/171.000
INCL
       INCLS: 514/252.000; 514/327.000; 514/382.000; 514/396.000; 514/812.000
NCL
              514/171.000
             514/254.070; 514/327.000; 514/382.000; 514/396.000; 514/812.000
       NCLS:
IC
       [6]
       ICM: A61K031-50
       ICS: A61K031-56; A61K031-495
       514/171; 514/252; 514/327; 514/382; 514/396; 514/812
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 12 OF 12 USPATFULL on STN
L5
       1998:57893 USPATFULL
AN
       Composition of pyruvate and anti-cortisol compounds and method for
ΤI
       increasing protein concentration in a mammal
       Beale, Paxton K., 1801 Bush St., Suite 300, San Francisco, CA, United
IN
       States 94109
                               19980526
       US 5756469
PΤ
                               19960726 (8)
AΙ
       US 1996-686820
       Utility
DT
       Granted
FS
LN.CNT 542
       INCLM: 514/023.000
INCL
       INCLS: 514/053.000; 514/078.000
              514/023.000
       NCLM:
NCL
             514/053.000; 514/078.000
       NCLS:
       [6]
IC
       ICM: A61K031-70
       ICS: A61K031-715; A61K031-685
       514/23; 514/53; 514/78
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

=> fil reg COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 31.67 32.30

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:40:43 ON 19 SEP 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2 DICTIONARY FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s fungoral/cn L6 1 FUNGORAL/CN

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN

RN 65277-42-1 REGISTRY

CN Piperazine, 1-acetyl-4-[4-[((2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-

OTHER NAMES:

CN (.+-.)-Ketoconazole

CN Fungarest

CN Fungoral

CN Ketoconazole

CN Ketoderm

CN Ketoisdin

CN Nizoral

CN Nizral

CN Orifungal M

CN Panfungol

CN R 41400

FS STEREOSEARCH

DR 72093-26-6

MF C26 H28 C12 N4 O4

CT COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)
Other Sources: EINECS\*\*, WHO
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2412 REFERENCES IN FILE CA (1937 TO DATE)
40 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2416 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> fil uspatful
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 6.30 38.60

<<<

<<<

FULL ESTIMATED COST

enter this cluster.

>>>

>>>

FILE 'USPATFULL' ENTERED AT 13:40:59 ON 19 SEP 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Sep 2003 (20030918/PD)
FILE LAST UPDATED: 18 Sep 2003 (20030918/ED)
HIGHEST GRANTED PATENT NUMBER: US6622308
HIGHEST APPLICATION PUBLICATION NUMBER: US2003177560
CA INDEXING IS CURRENT THROUGH 18 Sep 2003 (20030918/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Sep 2003 (20030918/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<< original, i.e., the earliest published granted patents or <<< >>> applications. USPAT2 contains full text of the latest US <<< publications, starting in 2001, for the inventions covered in <<< >>> USPATFULL. A USPATFULL record contains not only the original <<< published document but also a list of any subsequent <<< >>> publications. The publication number, patent kind code, and <<< >>> publication date for all the US publications for an invention <<< >>> are displayed in the PI (Patent Information) field of USPATFULL <<< >>> records and may be searched in standard search fields, e.g., /PN, <<< <<< >>> /PK, etc. USPATFULL and USPAT2 can be accessed and searched together <<< >>> through the new cluster USPATALL. Type FILE USPATALL to <<< >>>

```
>>> Use USPATALL when searching terms such as patent assignees,
                                                                         <<<
>>> classifications, or claims, that may potentially change from
                                                                         <<<
                                                                         <<<
>>> the earliest to the latest publication.
This file contains CAS Registry Numbers for easy and accurate
substance identification.
=> d his
     (FILE 'HOME' ENTERED AT 13:33:56 ON 19 SEP 2003)
     FILE 'USPATFULL' ENTERED AT 13:35:33 ON 19 SEP 2003
             57 S CORTISOL/TI, AB
L1
           8874 S (ANTAGONIST OR ANTAGONISTS)/TI, AB
L2
L3
             10 S L1 AND L2
              0 S (CORISOL(2A) (ANTAGONIST OR ANTAGONISTS))
L4
             12 S (CORTISOL(2A) (ANTAGONIST OR ANTAGONISTS))
1.5
     FILE 'REGISTRY' ENTERED AT 13:40:43 ON 19 SEP 2003
L6
              1 S FUNGORAL/CN
     FILE 'USPATFULL' ENTERED AT 13:40:59 ON 19 SEP 2003
=> s 16
           402 L6
1.7
=> s 17 and cortisol
          2763 CORTISOL
            29 L7 AND CORTISOL
L8
=> d 18 1-29
     ANSWER 1 OF 29 USPATFULL on STN
L8
       2003:200796 USPATFULL
AN
       Methods for determining steroid responsiveness
TΙ
       Whitehead, Alexander Steven, Wayne, PA, UNITED STATES
IN
                               20030724
PΤ
       US 2003138781
                          A1
                                20020122 (10)
       US 2002-45360
                          Α1
AΤ
DТ
       Utility
       APPLICATION
FS
LN.CNT 1661
       INCLM: 435/006.000
TNCL
       INCLS: 702/020.000
NCL
       NCLM: 435/006.000
             702/020.000
       NCLS:
IC
       [7]
       ICM: C120001-68
       ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 2 OF 29 USPATFULL on STN
L8
AN
       2003:188461 USPATFULL
       Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
ΤI
       Marfat, Anthony, UNITED STATES
TN
       McKechney, Michael William, UNITED STATES
ΡI
       US 2003130254
                          A1
                               20030710
                               20021120 (10)
       US 2002-300959
                          A1
AΙ
       Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING
RLI
                           20010131 (60)
PRAI
       US 2001-265486P
       Utility
DT
       APPLICATION
FS
LN.CNT 7168
INCL
       INCLM: 514/210.200
       INCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;
```

```
514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;
              514/314.000
NCL
       NCLM:
              514/210.200
              514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;
       NCLS:
              514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;
              514/314.000
IC
       [7]
       ICM: A61K031-541
       ICS: A61K031-5377; A61K031-506; A61K031-52; A61K031-517; A61K031-4709;
       A61K031-427; C07D417-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 3 OF 29 USPATFULL on STN
L8
AN
       2003:187370 USPATFULL
       Use of a polypeptide for treatment of pruritis in animals
ΤI
       Lipton, James M., Woodland Hills, CA, UNITED STATES
IN
       Catania, Anna P., Milan, ITALY
       US 2003129156
                          A1
                               20030710
PΤ
                          A1
                               20011217 (10)
       US 2001-23287
ΑI
DT
       Utility
FS
       APPLICATION
LN.CNT 1612
       INCLM: 424/070.210
INCL
       INCLS: 514/018.000; 514/014.000; 514/015.000; 514/016.000
       NCLM:
              424/070.210
NCL
              514/018.000; 514/014.000; 514/015.000; 514/016.000
       NCLS:
       [7]
IC
       ICM: A61K038-10
       ICS: A61K038-08; A61K038-05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 4 OF 29 USPATFULL on STN
L8
       2002:338241 USPATFULL
AN
       Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
ΤI
       Chambers, Robert J., Mystic, CT, UNITED STATES
IN
       Marfat, Anthony, Mystic, CT, UNITED STATES
       Magee, Thomas V., Mystic, CT, UNITED STATES
       Pfizer Inc. (U.S. corporation)
PA
                               20021219
       US 2002193612
                          A1
PI
                               20020131 (10)
       US 2002-62813
                          A1
ΑI
       US 2001-265492P
                           20010131 (60)
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 7001
       INCLM: 549/200.000
INCL
       NCLM: 549/200.000
NCL
       [7]
IC
       ICM: C07D321-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 5 OF 29 USPATFULL on STN
L8
       2002:228358 USPATFULL
AN
       Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives
ΤI
       useful as inhibitors of PDE4 isozymes
       Marfat, Anthony, Mystic, CT, UNITED STATES
IN
       McKechney, Michael William, Fairport, NY, UNITED STATES
       Pfizer Inc. (U.S. corporation)
PA
       US 2002123520
                          A1
                               20020905
PΙ
                          B2
                               20030506
       US 6559168
                          Α1
                               20020131 (10)
       US 2002-62145
AΙ
                          20010131 (60)
       US 2001-265486P
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 6963
```

```
INCL
       INCLM: 514/365.000
       INCLS: 514/398.000; 548/188.000; 548/323.100; 514/341.000; 514/342.000;
              546/269.700; 546/272.700
NCL
       NCLM:
              514/338.000
              514/342.000; 514/369.000; 514/370.000; 546/269.700; 548/188.000;
       NCLS:
              548/195.000; 548/196.000
IC
       [7]
       ICM: A61K031-4439
       ICS: A61K031-426; C07D417-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 6 OF 29 USPATFULL on STN
L8
AN
       2002:126742 USPATFULL
       Glucocorticoid blocking agents for increasing blood-brain barrier
ΤI
       permeability
       Schatzberg, Alan F., Los Altos, CA, UNITED STATES
TN
       Belanoff, Joseph K., Woodside, CA, UNITED STATES
       Lindley, Steven, Redwood City, CA, UNITED STATES
       US 2002065259
                          A1
                                20020530
PΙ
                                20010829 (9)
ΑI
       US 2001-942531
                          A1
                           20000830 (60)
       US 2000-229278P
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 962
INCL
       INCLM: 514/179.000
       NCLM: 514/179.000
NCL
IC
       [7]
       ICM: A61K031-57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
     ANSWER 7 OF 29 USPATFULL on STN
       2002:106303 USPATFULL
AN
       Compositions for delivery of a cortisol antagonist
TΙ
       Marin, Per, Vastra Frolunda, SWEDEN
IN
       Landh, Tomas, Lund, SWEDEN
       Ostholm, Ivan, Goteborg, SWEDEN
       CORTENDO AB. (non-U.S. corporation)
PΑ
                          A1
                                20020509
       US 2002055512
PΙ
                          A1
                                20010316 (9)
       US 2001-809979
AΙ
       Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,
RLT
       UNKNOWN
                           20000121
PRAI
       GB 2000-1449
       Utility
DТ
FS
       APPLICATION
LN.CNT 1462
       INCLM: 514/254.070
INCL
NCL
       NCLM: 514/254.070
IC
       [7]
       ICM: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 8 OF 29 USPATFULL on STN
L8
AN
       2002:48049 USPATFULL
       Timed-release compression-coated solid composition for oral
ΤI
       administration
       Sawada, Toyohiro, Fujieda-shi, JAPAN
TN
       Sako, Kazuhiro, Yaizu-shi, JAPAN
       Yoshioka, Tatsunobu, Yaizu-shi, JAPAN
       Watanabe, Shunsuke, Fujieda-shi, JAPAN
                         A1
                                20020307
       US 2002028240
PΙ
                          A1
                                20010412 (9)
       US 2001-834410
AΙ
                           20000417 (60)
       US 2000-198086P
PRAI
DT
       Utility
FS
       APPLICATION
```

```
LN.CNT 1794
       INCLM: 424/472.000
INCL
       INCLS: 514/215.000
       NCLM: 424/472.000
NCL
       NCLS: 514/215.000
IC
       [7]
       ICM: A61K009-24
       ICS: A61K031-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 9 OF 29 USPATFULL on STN
L8
       2002:37338 USPATFULL
AN
       Drug delivery system for averting pharmacokinetic drug interaction and
TI
       method thereof
       Sawada, Toyohiro, Fujieda-shi, JAPAN
ΙN
       Sako, Kazuhiro, Yaizu-shi, JAPAN
       Yoshioka, Tatsunobu, Yaizu-shi, JAPAN
       Watanable, Shunsuke, Fujieda-shi, JAPAN
                               20020221
                         A1
       US 2002022054
ΡI
       US 2001-834414
                          A1
                               20010412 (9)
AΙ
       US 2000-197574P
                           20000417 (60)
PRAI
DT
       Utility
FS
       APPLICATION
LN.CNT 1496
       INCLM: 424/468.000
INCL
       INCLS: 514/171.000; 514/304.000; 514/284.000
       NCLM: 424/468.000
NCL
              514/171.000; 514/304.000; 514/284.000
       NCLS:
IC
       [7]
       ICM: A61K009-22
       ICS: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 10 OF 29 USPATFULL on STN
1.8
       2001:131297 USPATFULL
AN
       Preparation for the treatment of metabolic syndrome containing human
ΤI
       growth hormone in combination with a cortisol synthesis
       inhibitor
       M.ang.rin, Per, Goteborg, Sweden
IN
       Cortendo AB, Vastra Frolunda, Sweden (non-U.S. corporation)
PA
                               20010814
       US 6274582
                          В1
PΙ
                               19990824 (9)
       US 1999-379832
ΑI
       Continuation of Ser. No. WO 1998-GB574, filed on 24 Feb 1998
RLI
                           19970224
       SE 1997-642
PRAI
DT
       Utility
       GRANTED
FS
LN.CNT 437
       INCLM: 514/254.100
INCL
       INCLS: 514/399.000; 514/012.000; 514/178.000; 514/179.000
       NCLM: 514/254.100
NCL
       NCLS: 514/012.000; 514/178.000; 514/179.000; 514/399.000
       [7]
IC
       ICM: A61K031-495
       ICS: A61K031-415; A61K038-00
       514/12; 514/178; 514/179; 514/254.1; 514/399
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 11 OF 29 USPATFULL on STN
L8
       2001:10889 USPATFULL
AN
       Treatment of glaucoma and ocular hypertension
ΤI
       Clark, Abbot F., Arlington, TX, United States
IN
       Conrow, Raymond E., Fort Worth, TX, United States
       Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S.
PA
       corporation)
```

```
В1
                               20010123
PΙ
       US 6177427
                               19990701 (9)
ΑI
       US 1999-346424
       Continuation of Ser. No. US 1997-858298, filed on 19 May 1997, now
RLI
       abandoned Continuation of Ser. No. US 1996-631041, filed on 12 Apr 1996,
       now abandoned Continuation of Ser. No. US 1994-268086, filed on 28 Jun
       1994, now abandoned
דת
       Utility
       Granted
FS
LN.CNT 473
       INCLM: 514/239.200
INCL
       INCLS: 514/255.000; 514/383.000; 514/396.000; 514/406.000; 544/177.000;
              544/396.000; 548/262.200; 548/373.100; 548/572.000
       NCLM:
              514/239.200
NCL
              514/255.040; 514/383.000; 514/396.000; 514/406.000; 544/177.000;
       NCLS:
              544/396.000; 548/262.200; 548/373.100; 548/572.000
       [7]
IC
       ICM: A61K031-415
       ICS: C07D231-10; C07D207-04; C07D265-30
       514/396; 514/397; 514/239.2; 514/255; 514/406; 514/383; 548/346.1;
EXF
       548/314.7; 548/262.2; 548/572; 548/373.1; 544/177; 544/396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 12 OF 29 USPATFULL on STN
Ľ8
       2001:4475 USPATFULL
AN
       Methods for releasing a ligand from a complex
TI
       Staples, Mark A., San Jose, CA, United States
IN
       Haley, Carolyn J., Morgan Hill, CA, United States
       Parrish, Richard F., San Jose, CA, United States
       Zmolek, Wesley W., Freemont, CA, United States
       Dade Behring Marburg GmbH, Marburg, Germany, Federal Republic of
PΑ
       (non-U.S. corporation)
                               20010109
       US 6171801
PΙ
                               19970717 (8)
ΑI
       US 1997-896244
                           19960718 (60)
       US 1996-22133P
PRAI
DT
       Patent
       Granted
FS
LN.CNT 1370
       INCLM: 435/007.100
INCL
       INCLS: 435/007.900; 435/961.000; 435/962.000; 436/177.000; 436/174.000;
              436/536.000; 436/825.000
              435/007.100
NCL
       NCLM:
              435/007.900; 435/961.000; 435/962.000; 436/174.000; 436/177.000;
       NCLS:
              436/536.000; 436/825.000
       [7]
IC
       ICM: G01N033-53
       ICS: G01N033-531; G01N001-18; G01N001-00
       435/7.9; 435/7.1; 435/962; 435/961; 436/501; 436/174; 436/825; 436/177;
EXF
       436/536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 13 OF 29 USPATFULL on STN
L8
       2000:174644 USPATFULL
AN
       Method of using ketoconazole and related substances in medicaments for
TI
       treatment of type II diabetes and methods of treating same
       Marin, Per, Goteborg, Sweden
ΙN
       Cortendo, AB, Gothenburg, Sweden (non-U.S. corporation)
PΑ
       US 6166017
                                20001226
ΡI
                               19981214 (9)
       US 1998-211282
ΑI
       Continuation of Ser. No. US 776983
RLI
DT
       Utility
FS
       Granted
LN.CNT 238
       INCLM: 514/247.000
INCL
       INCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000
```

```
NCL
       NCLM:
              514/247.000
              514/178.000; 514/396.000; 514/467.000; 514/866.000
       NCLS:
IC
       [7]
       ICM: A61K031-50
       ICS: A61K031-56; A61K031-415; A61K031-335
       514/247; 514/178; 514/396; 514/467; 514/866
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    ANSWER 14 OF 29 USPATFULL on STN
L8
       2000:47230 USPATFULL
AN
       Treatment of GLC1A glaucoma with non-steroidal glucocorticoid
TI
       antagonists
       Clark, Abbot F., Arlington, TX, United States
IN
       Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S.
PA
       corporation)
       US 6051573
                               20000418
PΙ
       US 1997-994957
                               19971219 (8)
ΑI
       Continuation-in-part of Ser. No. US 1997-858298, filed on 19 May 1997,
RLI
       now abandoned which is a continuation-in-part of Ser. No. US
       1996-631041, filed on 12 Apr 1996, now abandoned which is a continuation
       of Ser. No. US 1994-268086, filed on 28 Jun 1994, now abandoned
       Utility
DT
       Granted
FS
LN.CNT 638
       INCLM: 514/235.500
INCL
       INCLS: 514/239.200; 514/255.000; 514/333.000; 514/340.000; 514/341.000;
              514/343.000; 514/359.000; 514/424.000; 514/425.000; 514/427.000;
              514/428.000; 514/408.000
              514/235.500
NCL
       NCLM:
              514/239.200; 514/252.100; 514/252.110; 514/253.090; 514/255.050;
       NCLS:
              514/333.000; 514/340.000; 514/341.000; 514/343.000; 514/359.000;
              514/408.000; 514/424.000; 514/425.000; 514/427.000; 514/428.000
       [7]
IC
       ICM: A61K031-535
       ICS: A01N043-60; A01N043-40; A01N043-64; A01N043-36
       514/235.5; 514/239.2; 514/255; 514/333; 514/340; 514/341; 514/343;
EXF
       514/359; 514/424; 514/425; 514/427; 514/428; 514/408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
    ANSWER 15 OF 29 USPATFULL on STN
L8
       1999:19138 USPATFULL
AN
       Low dosage treatment for cocaine craving and withdrawal
TI
       Goeders, Nicholas E., Shreveport, LA, United States
IN
       Board of Supervisors of Louisiana State University and Agricultural and
PA
       Mechanical College, Baton Rouge, LA, United States (U.S. corporation)
                               19990209
       US 5869474
PΙ
       US 1997-857376
                               19970516 (8)
ΑI
DT
       Utility
       Granted ·
FS
LN.CNT 732
       INCLM: 514/171.000
INCL
       INCLS: 514/252.000; 514/327.000; 514/382.000; 514/396.000; 514/812.000
NCL
       NCLM:
              514/171.000
              514/254.070; 514/327.000; 514/382.000; 514/396.000; 514/812.000
       NCLS:
       [6]
IC
       ICM: A61K031-50
       ICS: A61K031-56; A61K031-495
       514/171; 514/252; 514/327; 514/382; 514/396; 514/812
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 16 OF 29 USPATFULL on STN
L8
       1998:157342 USPATFULL
AN
       Methods for using ketoconazole and related substances in medicaments for
ΤI
       treatment of type II diabetes
```

```
Marin, Per, Goteborg, Sweden
IN
       Cortendo AB, Gothenburg, Sweden (non-U.S. corporation)
PA
                               19981215
ΡI
       US 5849740
       WO 9604912 19960222
                               19970206 (8)
ΑI
       US 1997-776983
       WO 1994-SE729
                               19940809
                               19970206 PCT 371 date
                               19970206 PCT 102(e) date
DT
       Utility
       Granted
FS
LN.CNT 174
       INCLM: 514/247.000
INCL
       INCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000
NCL
              514/247.000
              514/178.000; 514/396.000; 514/467.000; 514/866.000
      NCLS:
IC
       [6]
       ICM: A61K031-50
       ICS: A61K031-56; A61K031-415; A61K031-335
       514/247; 514/396; 514/467; 514/866; 514/178
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 17 OF 29 USPATFULL on STN
L8
       1998:33606 USPATFULL
AN
       Gas and gaseous precursor filled microspheres as topical and
TI
       subcutaneous delivery vehicles
       Unger, Evan C., Tucson, AZ, United States
IN
       Matsunaga, Terry O., Tucson, AZ, United States
       Yellowhair, David, Tucson, AZ, United States
       ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PA
       US 5733572
                               19980331
ΡI
       US 1994-346426
                               19941129 (8)
ΑI
       Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994
RLI
       Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented,
       Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov
       1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674,
       filed on 30 Nov 1993, now abandoned , said Ser. No. US
                                                                 -159687 Ser.
                         -160232 And Ser. No. US
                                                   -159674 , each Ser. No. US
       No. Ser. No. US
       - which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11
       Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250,
       filed on 11 Jun 1993, now patented, Pat. No. US 5580575 , said Ser. No.
            -76239 And Ser. No. US
                                     -76250 , each Ser. No. US
       continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991,
       now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on
       18 Jun 1991, now abandoned , said Ser. No. US
                                                       -717084 And Ser. No. US

    which is a continuation-in-part of Ser.

       -716899 , each Ser. No. US
       No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US
       5088499 which is a continuation-in-part of Ser. No. US 1989-455707,
       filed on 22 Dec 1989, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 4174
       INCLM: 424/450.000
INCL
       INCLS: 424/121.000; 424/009.321; 424/009.400; 424/489.000; 436/829.000
NCL
              424/450.000
       NCLM:
              424/001.210; 424/009.321; 424/009.400; 424/489.000; 436/829.000
       NCLS:
IC
       [6]
       ICM: A61K009-127
       424/450; 424/1.21; 424/9.321; 424/9.4; 424/489; 436/829
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 18 OF 29 USPATFULL on STN
L8
       97:73588 USPATFULL
AN
       Method for topical inhibition of the metabolic activity of cytochrome
TI
       P450
```

```
Gelland, Yuri, Pittsburgh, PA, United States
IN
       Wolf, Bruce L., Nashville, TN, United States
       TWK, Inc., Nashville, TN, United States (U.S. corporation)
PA
                               19970819
PΤ
       US 5658881
                               19941014 (8)
       US 1994-323267
ΑI
DT
       Utility
       Granted
FS
LN.CNT 352
       INCLM: 514/011.000
TNCL
       INCLS: 514/171.000; 514/252.000; 514/399.000
       NCLM:
              514/011.000
NCL
              514/171.000; 514/254.070; 514/399.000
       NCLS:
IC
       [6]
       ICM: A61K031-57
       ICS: A61K031-415; A61K031-495; A61K038-13
       514/171; 514/252; 514/399; 514/11
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 19 OF 29 USPATFULL on STN
L8
       96:77760 USPATFULL
AN
       Combination therapy for the treatment of estrogen-sensitive disease
ΤI
       Labrie, Fernand, Quebec, Canada
IN
       Endorecherche Inc., Quebec, Canada (non-U.S. corporation)
PA
                                19960827
       US 5550107
PΙ
                                19911104 (7)
       US 1991-785890
ΑI
       Continuation of Ser. No. US 1989-321926, filed on 10 Mar 1989, now
RLI
       abandoned
DT
       Utility
FS
       Granted
LN.CNT 1665
       INCLM: 514/011.000
INCL
       INCLS: 514/015.000; 514/169.000; 514/170.000; 514/161.000; 514/255.000;
              514/328.000; 514/649.000; 514/617.000
              514/011.000
NCL
       NCLM:
              514/015.000; 514/169.000; 514/170.000; 514/171.000; 514/250.000;
       NCLS:
              514/328.000; 514/617.000; 514/649.000
IC
       [6]
       ICM: A61K038-00
       ICS: A61K031-56; A61K031-495; A61K031-50; A61K031-445; A61K031-165;
       A61K031-135
       514/11; 514/15; 514/169; 514/170; 514/171; 514/255; 514/328; 514/617;
EXF
       514/649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 20 OF 29 USPATFULL on STN
L8
       95:62727 USPATFULL
AN
       Method of retarding the progression of chronic renal failure
TI
       Walser, Mackenzie, Ruxton, MD, United States
TN
       The John Hopkins University, Baltimore, MD, United States (U.S.
PA
       corporation)
                                19950711
PI
       US 5432176
                                19921224 (7)
       US 1992-996757
AΙ
       Continuation-in-part of Ser. No. US 1988-277161, filed on 29 Nov 1988,
RLI
       now patented, Pat. No. US 5175144
       Utility
DT
FS
       Granted
LN.CNT 471
       INCLM: 514/252.000
INCL
       INCLS: 514/002.000; 514/011.000; 514/171.000; 514/289.000; 514/327.000
             514/254.070
NCL
       NCLS: 514/002.000; 514/011.000; 514/171.000; 514/289.000; 514/327.000
IC
       [6]
       ICM: A61K031-495
       ICS: A61K031-50; A61K037-00; A61K031-56
```

```
514/2; 514/11; 514/179; 514/252; 514/282; 514/289; 514/327; 514/171
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 21 OF 29 USPATFULL on STN
L8
       92:106806 USPATFULL
AN
       Method of retarding the progression of chronic renal failure
ΤI
       Walser, Mackenzie, Ruxton, MD, United States
IN
       The Johns Hopkins University, Baltimore, MD, United States (U.S.
PA
       corporation)
                                19921229
PΙ
       US 5175144
                               19881129 (7)
       US 1988-277161
AΙ
       Utility
DT
       Granted
FS
LN.CNT 476
INCL
       INCLM: 514/002.000
       INCLS: 514/011.000; 514/179.000; 514/252.000; 514/282.000; 514/289.000;
              514/327.000
NCL
              514/002.000
       NCLM:
              514/011.000; 514/179.000; 514/254.070; 514/282.000; 514/289.000;
       NCLS:
              514/327.000
IC
       [5]
       ICM: A61K037-00
       ICS: A61K031-56; A61K021-495; A61K031-50; A61K031-44; A61K031-445
       514/179; 514/2; 514/11; 514/252; 514/282; 514/289; 514/327
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 22 OF 29 USPATFULL on STN
rs
       91:92512 USPATFULL
AN
       Combination therapy for selected sex steroid dependent cancers
ΤI
       Labrie, Fernand, 2735 Boul. Ilgeois, Ste-Foy, Quebec, Canada G1W 1Z9
IN
                                19911112
PΙ
       US 5064813
       US 1989-413613
                               19891109 (7)
ΑI
       Continuation of Ser. No. US 1988-146597, filed on 21 Jan 1988, now
RLI
       abandoned which is a continuation of Ser. No. US 1986-892214, filed on
       31 Jul 1986, now patented, Pat. No. US 4760053
DT
       Utility
       Granted
FS
LN.CNT 952
       INCLM: 514/015.000
INCL
       INCLS: 514/177.000; 514/178.000; 514/358.000; 514/800.000
              514/015.000
NCL
       NCLM:
              514/128.000; 514/177.000; 514/358.000; 514/800.000
       NCLS:
IC
       [5]
       ICM: A61K037-02
       514/15; 514/177; 514/178; 514/358; 514/800
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 23 OF 29 USPATFULL on STN
L8
       91:46693 USPATFULL
AN
       Combination male breast cancer therapy
TI
       Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, Canada G1W 1Z9
ΙN
                               19910611
       US 5023234
PΙ
       US 1985-699710
                               19850208 (6)
ΑI
       Utility
DT
FS
       Granted
LN.CNT 572
       INCLM: 514/015.000
INCL
       INCLS: 514/392.000; 514/649.000
NCL
              514/015.000
       NCLM:
             514/392.000; 514/649.000
       NCLS:
IC
       [5]
       ICM: A61K037-02
       ICS: C07K007-06
       514/15
EXF
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 24 OF 29 USPATFULL on STN
L8
       89:92340 USPATFULL
AN
       Lipid nano-pellets as excipient system for perorally administered drugs
ΤI
       Speiser, Peter, Zurich, Switzerland
TN
       Dr. Rentschler Arzneimittel GmbH & Co., Laupheim, Germany, Federal
PA
       Republic of (non-U.S. corporation)
PΙ
       US 4880634
                               19891114
                                19870626 (7)
ΑI
       US 1987-66459
       Continuation of Ser. No. US 1985-740771, filed on 30 Jun 1985, now
RLI
       abandoned
                           19840608
       DE 1984-3421468
PRAI
       Utility
DТ
FS
       Granted
LN.CNT 820
       INCLM: 424/450.000
INCL
       INCLS: 424/502.000; 514/786.000
NCL
       NCLM: 424/450.000
              424/502.000; 514/786.000
       NCLS:
IC
       [4]
       ICM: A61K037-22
       TCS: A61K009-50; A61K047-00
       514/786; 514/943; 514/938; 514/937; 514/964; 424/502; 424/450
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 25 OF 29 USPATFULL on STN
L8
       89:21171 USPATFULL
AN
       Method for treatment of hypercortisolemic, depressed patients
TΙ
       Ravaris, Charles L., Hanover, NH, United States
IN
       The Trustees of Dartmouth College, Hanover, NH, United States (U.S.
PA
       corporation)
                                19890321
       US 4814333
PΤ
                                19880210 (7)
       US 1988-154338
ΑI
       Continuation-in-part of Ser. No. US 1987-78814, filed on 28 Jul 1987,
RLI
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 360
       INCLM: 514/255.000
INCL
       NCLM: 514/254.070
NCL
IC
       [4]
       ICM: A61K031-495
       514/255
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 26 OF 29 USPATFULL on STN
L8
       88:64035 USPATFULL
AN
       Combination therapy for treatment of female breast cancer
ΤI
       Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada
IN
                                19881004
       US 4775661
PΙ
       US 1987-47830
                                19870506 (7)
ΑI
       Division of Ser. No. US 1985-699702, filed on 8 Feb 1985, now patented,
RLI
       Pat. No. US 4666885
       Utility
DT
       Granted
FS
LN.CNT 498
       INCLM: 514/015.000
INCL
       INCLS: 514/800.000; 206/219.000
              514/015.000
NCL
       NCLM:
              206/219.000; 514/800.000; 930/020.000; 930/021.000; 930/130.000
       NCLS:
       [4]
IC
       ICM: A61K037-24
       ICS: B65D077-04
```

```
206/219; 514/15; 514/800
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 27 OF 29 USPATFULL on STN
L8
       88:47260 USPATFULL
AN
       Combination therapy for selected sex steroid dependent cancers
TI
       Labrie, Fernand, 2735 boul. Liegeois, Ste-Foy, Quebec, Canada G1W 1Z9
TN
                                19880726
       US 4760053
PT
                                19860731 (6)
       US 1986-892214
AΙ
       WO 1985-US1454
                            19850802
PRAI
       Utility
DT
       Granted
FS
LN.CNT 1029
       INCLM: 514/015.000
INCL
       INCLS: 514/177.000; 514/178.000; 514/800.000; 514/358.000
              514/015.000
NCL
       NCLM:
              514/177.000; 514/178.000; 514/358.000; 514/800.000; 930/010.000;
       NCLS:
              930/020.000; 930/021.000; 930/130.000
IC
       [4]
       ICM: A61K037-43
       530/328; 530/313; 514/178; 514/800; 514/177; 514/358; 514/15
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 28 OF 29 USPATFULL on STN
L8
       87:36065 USPATFULL
AN
       Combination therapy for treatment of female breast cancer
ΤI
       Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada
IN
       US 4666885
                                19870519
ΡI
                                19850208 (6)
       US 1985-699702
ΑI
       Utility
DT
       Granted
FS
LN.CNT 656
       INCLM: 514/015.000
INCL
       NCLM: 514/015.000
NCL
       NCLS: 930/020.000; 930/021.000; 930/130.000
       [4]
IC
       ICM: A61K037-24
       260/112.5R; 514/15
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 29 OF 29 USPATFULL on STN
L8
       87:28333 USPATFULL
ΑN
       Method of treatment of prostate cancer
ΤI
       Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada
IN
                                19870421
       US 4659695
PT
                                19850208 (6)
       US 1985-699711
AΙ
       Utility
DT
       Granted
FS
LN.CNT 604
       INCLM: 514/015.000
INCL
       INCLS: 514/800.000
       NCLM: 514/015.000
NCL
       NCLS: 514/800.000
       [4]
IC
       ICM: A61K037-24
       514/15; 514/800
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
=> d 28 hit
     ANSWER 28 OF 29 USPATFULL on STN
L_8
       When an inhibitor of adrenal sex steroid biosynthesis, e.g.,
DETD
       aminoglutethimide is administered, cortisol biosynthesis is
```



blocked. Accordingly, hydrocortisone is administered in physiological amounts sufficient to maintain normal glucocorticoid levels.

IT 50-23-7 125-84-8 13311-84-7 65277-42-1 (neoplasm inhibition with antiandrogens and antiestrogens and)

=> d 21 hit

L8 ANSWER 21 OF 29 USPATFULL on STN

DETD Glucocorticoids are corticosteroids predominantly affecting carbohydrate metabolism. Endogenous glucocorticoids influence fat and protein metabolism and have many other activities, such as affecting muscle tone and the excitation of nerve tissue and the microcirculation. In humans, the most important glucocorticoid is cortisol (hydrocortisone).

(1) Sodium valproate: This is an anticonvulsant, widely used, but not without serious side effects and toxicity. It has recently been shown to reduce serum cortisol levels by more than fifty percent within a few hours in normal subjects. Aggernaes, H. et al., "The Effect of Sodium Valproate on Serum Cortisol Levels in Healthy Subjects and Depressed Patients," Acta Psychiatr. Scand., 77:170-174 (1988).

(2) Enkephalins: These pentapeptides and their synthetic analogs, notably "DAMME" ([D-ala.sup.2, MePhe.sup.4, Met(O)-ol] enkephalin), reduce cortisol levels acutely in man. Stubbs, W. A., et al., "Hormonal and Metabolic Responses to an Enkephalin Analog in Normal Man", The Lancet, 1978:1225-1227 (Dec. 9, 1978); and Taylor, T., "Beta-Endorphin Suppresses Adrenocorticotropin and Cortisol Levels in Normal Human Subjects," Journal of Clinical Endocrinology and Metabolism, 57:592-596 (1983).

(3) Opioids: Alkaloids like morphine also interact with the same or DETD similar receptors as enkephalins. Opioids shown to decrease cortisol levels in man include morphine, pentazocine, nalorphine and buprenorphine. Pende, A., et al., "Evaluation of the Effects Induced by Four Opiate Drugs, with Different Affinity to Opioid Receptor Subtypes, on Interior Pituitary LH, TSH, PRL and GH Secretion and on Cortisol Secretion in Normal Man, " Biomed Pharmacother, 40:178-82 (1986). Chronic administration of these may not be practical owing to side effects and/or addictive properties. However, loperamide, commercially available under the trademark "IMODIUM" from Janssen Pharmaceutica, N. V., is not addictive, but does suppress adrenocorticotrophic hormone production. See Ambrosi, B., et al., "Loperamide, an Opiate Analog, Inhibits Plasma ACTH Levels in Patients with Addison's Disease," Clinical Endocrinology, 24:483-489 (1986). Loperamine and similar butyramides are described in U.S. Pat. No. 3,714,159 of Janssen, et al.

OETD (4) Clonidine: This widely used antihypertensive drug has recently been shown to lower cortisol levels in man. See
Slowinska-Srzednicka, J., et al., "Effect of Clonidine on Beta-Endorphin, ACTH and Cortisol Secretion in Essential Hypertension and Obesity," European Journal of Clinical Pharmacology, 35:115-121 (1988); and Lechin, F., et al. "Role of Stress in the Exacerbation of Chronic Illness: Effects of Clonidine Administration on Blood Pressure and Plasma Norepinephrine, Cortisol, Growth Hormone and Prolactin Concentrations," Psychoneuroendocrinology, 12:117-129 (1987). Clonidine is already commonly used to treat hypertension in patients with chronic renal failure.

DETD (5) Ketoconazole: This is an antifungal agent found to inhibit adrenocortical glucocorticoid production profoundly or even completely. Farwell, A. P., et al., "Total Suppression of Cortisol Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic Hormone Syndrome," The American Journal of Medicine, 84:1063-1066 (1988). However, ketoconazole is quite toxic.

DETD (6) Oxytocin: Intravenous infusion of this hormone (widely used to induce labor) lowers cortisol levels in normal men. Legros, J.

J., et al. "Confirmation of the Inhibitory Influence of Exogenous Oxytocin on Cortisol and ACTH in Man: Evidence of Reproducability, " ACTA Endocrinologica, 114:345-349 (1987). Oxytocin can be given as an intranasal spray, and side effects are minor. al studies 57-27-2, Morphine, biological 1069-66-5, Sodium valproate 64854-64-4 50-56-6, Oxytocin, biological studies IT 561-27-3, Heroin studies 84371-65-3, Mifepristone DAMME 65277-42-1, Ketoconazole (chronic renal failure progression retardation with, as agent suppressing glucocorticoids prodn., in human) => s 18 and (heart or cardiac) 95773 HEART 42578 CARDIAC 5 L8 AND (HEART OR CARDIAC) L9 => d 19 1-5 ANSWER 1 OF 5 USPATFULL on STN L9 AN 2003:188461 USPATFULL Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes TI Marfat, Anthony, UNITED STATES IN McKechney, Michael William, UNITED STATES US 2003130254 **A**1 20030710 ΡI US 2002-300959 A1 20021120 (10) AΙ Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING RLIUS 2001-265486P 20010131 (60) PRAI Utility DT APPLICATION FS LN.CNT 7168 TNCL INCLM: 514/210.200 INCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200; 514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000; 514/314.000 NCL NCLM: 514/210.200 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200; NCLS: 514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000; 514/314.000 IC [7] ICM: A61K031-541 ICS: A61K031-5377; A61K031-506; A61K031-52; A61K031-517; A61K031-4709; A61K031-427; C07D417-02 CAS INDEXING IS AVAILABLE FOR THIS PATENT. ANSWER 2 OF 5 USPATFULL on STN L9 2002:338241 USPATFULL AN Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes TIChambers, Robert J., Mystic, CT, UNITED STATES IN Marfat, Anthony, Mystic, CT, UNITED STATES Magee, Thomas V., Mystic, CT, UNITED STATES Pfizer Inc. (U.S. corporation) PAUS 2002193612 **A1** 20021219 PΤ 20020131 (10) ΑI US 2002-62813 A1 20010131 (60) US 2001-265492P PRAI DTUtility APPLICATION FS LN.CNT 7001 INCLM: 549/200.000 INCL NCL NCLM: 549/200.000 IC [7] ICM: C07D321-00 CAS INDEXING IS AVAILABLE FOR THIS PATENT. L9 ANSWER 3 OF 5 USPATFULL on STN

```
AN
       2002:228358 USPATFULL
       Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives
ΤI
       useful as inhibitors of PDE4 isozymes
       Marfat, Anthony, Mystic, CT, UNITED STATES
IN
       McKechney, Michael William, Fairport, NY, UNITED STATES
       Pfizer Inc. (U.S. corporation)
PA
                          A1
                               20020905
       US 2002123520
PΙ
                               20030506
       US 6559168
                          B2
                               20020131 (10)
                          A1
ΑI
       US 2002-62145
                           20010131 (60)
       US 2001-265486P
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 6963
INCL
       INCLM: 514/365.000
       INCLS: 514/398.000; 548/188.000; 548/323.100; 514/341.000; 514/342.000;
              546/269.700; 546/272.700
              514/338.000
NCL
       NCLM:
              514/342.000; 514/369.000; 514/370.000; 546/269.700; 548/188.000;
       NCLS:
              548/195.000; 548/196.000
IC
       [7]
       ICM: A61K031-4439
       ICS: A61K031-426; C07D417-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 4 OF 5 USPATFULL on STN
Ь9
AN
       1998:33606 USPATFULL
       Gas and gaseous precursor filled microspheres as topical and
TI
       subcutaneous delivery vehicles
       Unger, Evan C., Tucson, AZ, United States
IN
       Matsunaga, Terry O., Tucson, AZ, United States
       Yellowhair, David, Tucson, AZ, United States
       ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PΑ
                               19980331
PΙ
       US 5733572
                               19941129 (8)
       US 1994-346426
ΑI
       Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994
RLI
       Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented,
       Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov
       1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674,
       filed on 30 Nov 1993, now abandoned , said Ser. No. US
                                                                 -159687 Ser.
                                                  -159674 , each Ser. No. US
                         -160232 And Ser. No. US
       No. Ser. No. US
       - which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11
       Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250,
       filed on 11 Jun 1993, now patented, Pat. No. US 5580575, said Ser. No.
                                     -76250 , each Ser. No. US
                                                                 - which is a
            -76239 And Ser. No. US
       continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991,
       now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on
                                                       -717084 And Ser. No. US
       18 Jun 1991, now abandoned , said Ser. No. US

    which is a continuation-in-part of Ser.

       -716899 , each Ser. No. US
       No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US
       5088499 which is a continuation-in-part of Ser. No. US 1989-455707,
       filed on 22 Dec 1989, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 4174
       INCLM: 424/450.000
INCL
       INCLS: 424/121.000; 424/009.321; 424/009.400; 424/489.000; 436/829.000
NCL
              424/450.000
              424/001.210; 424/009.321; 424/009.400; 424/489.000; 436/829.000
       NCLS:
IC
       [6]
       ICM: A61K009-127
       424/450; 424/1.21; 424/9.321; 424/9.4; 424/489; 436/829
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L9 ANSWER 5 OF 5 USPATFULL on STN

89:92340 USPATFULL AN Lipid nano-pellets as excipient system for perorally administered drugs ΤI Speiser, Peter, Zurich, Switzerland IN Dr. Rentschler Arzneimittel GmbH & Co., Laupheim, Germany, Federal PA Republic of (non-U.S. corporation) 19891114 ΡI US 4880634 19870626 (7) US 1987-66459 ΑI Continuation of Ser. No. US 1985-740771, filed on 30 Jun 1985, now RLI abandoned 19840608 DE 1984-3421468 PRAI DTUtility FS Granted LN.CNT 820 INCLM: 424/450.000 INCL INCLS: 424/502.000; 514/786.000 NCL NCLM: 424/450.000 NCLS: 424/502.000; 514/786.000 IC [4] ICM: A61K037-22 ICS: A61K009-50; A61K047-00 514/786; 514/943; 514/938; 514/937; 514/964; 424/502; 424/450 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
65277-42-1 REGISTRY
RN
     Piperazine, 1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-
     1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX
     NAME)
OTHER CA INDEX NAMES:
     Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-
     ylmethyl) -1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-
OTHER NAMES:
CN
     (.+-.)-Ketoconazole
CN
     Fungarest
CN
     Fungoral
     Ketoconazole
CN
     Ketoderm
CN
CN
     Ketoisdin
     Nizoral
CN
     Nizral
CN
     Orifungal M
CN
CN
     Panfungol
     R 41400
CN
FS
     STEREOSEARCH
     72093-26-6
DR
     C26 H28 Cl2 N4 O4
MF
CI
     COM
                  ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
LC
     STN Files:
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,
       CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
       DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
       MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:
                      EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

Relative stereochemistry.